MONTREAL (CANADA) – March 30, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.
Details are as follows:
Date: Wednesday, April 21, 2021
Time: 4 pm ET
Format: 30-minute live virtual presentation, including Q&A
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. For more information or registration, please visit bloomburton.com.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy.
– 30 –
François Ravenelle, PhD
CEO & Founder
Inversago Pharma inc.